The Clinical Efficacy Of Docetaxel Combined With Lobaplatin In The Treatment Of Nasopharyngeal Carcinoma

ObjectiveExploring a novel treatment model for the comprehensive treatment of nasopharyngeal carcinoma patients,the clinical value of docetaxel combined with lobaplatin in concurrent chemoradiotherapy was discussed by examining treatment-related compliance,side effects,short-term efficacy and survival analysis.MethodsAfter a retrospective examination of those with nasopharyngeal squamous cell carcinoma who were treated in our department between January 2012 and October 2022,the chemotherapy scheme during the concurrent chemoradiotherapy period was used to divide them into two groups:docetaxel combined with lobaplatin chemotherapy and single drug lobaplatin chemotherapy.The patients were followed up by telephone and outpatient reexamination,supplemented by historical medical records to determine the survival status of the patients.The toxicity and side effects of the two groups during concurrent chemoradiotherapy and the results of MRI,neck ultrasound,double supraclavicular ultrasound,lung CT,abdominal ultrasound and other examinations three months after the end of all treatment plans were compared.Statistical methods pertinent to the matter can reveal the disparities between the two groups in terms of treatment adherence,short-term effectiveness,toxic and side effects related to treatment,the occurrence of associated clinical endpoints,and the long-term survival rate.An evaluation of the clinical value of concurrent chemoradiotherapy with docetaxel and lobaplatin,in the comprehensive treatment mode of nasopharyngeal carcinoma,was conducted by comparing long-term disease-free survival rate and other aspects.Results（1）The treatment-related compliance of TP group was 82.7%,and that of P group was 89.6%,P=0.109,P>0.05.There was no significant difference between the two groups.（2）The total remission rate of TP group（85.7%）was superior to the total remission rate of P group（72.3%）after treatment had been completed.The TP group（100%）achieved an objective effective rate that was significantly higher than the P group（98.2%）,p=0.030,p<0.05,making the difference statistically significant.（3）No significant distinction between the TP and P groups in terms of treatment-related side effects,such as bone marrow suppression and harm to liver or kidney function（P>0.05）,was revealed by the analysis of all patients.（4）A statistically significant difference was revealed by the analysis of the incidence of clinical end points,with TP group（83.0%）having a higher total survival rate than P group（67.9%）,P=0.008,P<0.05.The TP group（73.2%）demonstrated a significantly higher total disease-free survival rate than the P group（60.7%）,p=0.047,p<0.05,making the difference statistically significant.（5）A comparison of all patients’survival revealed that the TP group had a significantly higher 1-year OS（97.3%compared to 95.5%）,3-year OS（87.9%compared to 86.1%）,and 5-year OS（83.2%compared to 71.6%）（P=0.029,P<0.05）.The statistical significance of the difference was striking.No significant disparity was observed between the TP and P groups in the 1 year DFS（97.3%vs.92.9%）,3 years DFS（80.0%vs.79.0%）and 5 years DFS（70.4%vs.57.3%）tests（P=0.228,P>0.05）,indicating that the difference was not statistically significant.（6）The TP group demonstrated a statistically significant improvement in both overall survival rate（P=0.005,P<0.05）and disease-free survival rate（P=0.003,P<0.05）when compared to the P group in patients with stage T_3-4nasopharyngeal carcinoma.（7）No significant distinction was observed between TP and P groups in terms of total survival rate（P=0.079,P>0.05）or disease-free survival rate（P=0.385,P>0.05）when examining patients with stage N_2-3nasopharyngeal carcinoma.（8）A significant difference in total survival rate between TP and P groups was revealed by the analysis of patients suffering from nasopharyngeal carcinoma of clinical stages III and IV A（P=0.018,P<0.05）.There was no significant difference in disease-free survival rate between TP group and P group（P=0.113,P>0.05）.ConclusionDuring radiotherapy and chemotherapy,docetaxel combined with lobaplatin was used as the concurrent chemoradiotherapy scheme.Compared with lobaplatin alone as the concurrent chemoradiotherapy scheme,there was no significant difference between the two groups in terms of treatment-related compliance and related side effects;However,TP group has excellent short-term curative effect and obvious benefit in long-term overall survival rate;A Cox regression model of multivariate risk analysis reveals that the selection of chemotherapy regimen in concurrent chemoradiotherapy is a distinct risk factor influencing the survival and outlook of those suffering from nasopharyngeal carcinoma.A stratified analysis of some nasopharyngeal carcinoma patients,compared to group P,revealed a disparity.The overall survival rate and disease-free survival rate of patients suffering from nasopharyngeal carcinoma can be significantly enhanced through concurrent chemoradiotherapy with TP.concurrent chemoradiotherapy with TP can be recommended because of its low toxicity and good curative effect in the near term.